One-carbon Therapeutics AB

One-carbon Therapeutics AB is a clinical-stage biotechnology company headquartered in Solna, Sweden. It was founded as a spin-out from the Karolinska Institute and is focused on exploiting cancer's dependence on one-carbon metabolism — the biochemical network that supports rapid DNA synthesis and cancer cell survival. The company describes itself as translating deep mechanistic biological understanding into differentiated clinical assets. Its lead programme, TH9619, is a first-in-class, potent, small-molecule dual inhibitor of MTHFD1 and MTHFD2. The compound is designed to selectively kill cancer cells through a mechanism the company calls "folate trapping." In cancer cells, high MTHFD2 expression drives the release of formate from mitochondria into the cytosol to generate 10-CHO-THF (formylfolate). Inhibition of MTHFD1 by TH9619 prevents further use of 10-CHO-THF for downstream thymidylate synthesis, creating a folate trap that depletes the folate (THF) needed for thymidylate production. This results in nucleotide shortage, DNA damage, and cancer cell death. Normal cells lack MTHFD2 expression and the formate overflow needed to create this trap, which the company believes provides a selectivity window. The company is targeting difficult-to-treat advanced refractory solid tumours. TH9619 is currently being evaluated in the Phase 1/2 ODIN study. One-carbon Therapeutics has stated that by identifying early signs of anti-tumour activity and guiding rational indication selection, it aims to build the foundation for a new generation of more precise and more tolerable cancer treatments. The company's team is described as having extensive experience in oncology, drug discovery, and development. In May 2026, One-carbon Therapeutics announced the appointment of Stefan Larsson and Raj Shah to its Board of Directors, and it announced that it would present a trial-in-progress poster on the ODIN Phase 1/2 study of TH9619 at the 2026 ASCO Annual Meeting. The company is headquartered in Sweden and is committed to translating cutting-edge metabolic science into transformative clinical impact for patients worldwide.

One-carbon Therapeutics AB was founded as a spin-out from the Karolinska Institute, one of Sweden's leading medical universities, and is headquartered in Solna, Sweden. The company was established to exploit cancer's dependence on one-carbon metabolism — a biochemical pathway that supports rapid DNA synthesis and cancer cell survival. Its founding was rooted in deep mechanistic biological understanding of this metabolic dependency. The company's lead programme, TH9619, is a first-in-class, potent, small-molecule dual inhibitor of MTHFD1 and MTHFD2. TH9619 was developed based on strong preclinical data and is designed to selectively kill cancer cells through folate trapping. In cancer cells, high MTHFD2 expression drives the release of formate from mitochondria into the cytosol to generate 10-CHO-THF (formylfolate). Inhibition of MTHFD1 by TH9619 prevents further use of 10-CHO-THF for downstream thymidylate synthesis, creating a folate trap that depletes the folate (THF) necessary for thymidylate production. This results in nucleotide shortage, DNA damage, and cancer cell death. Normal cells lack MTHFD2 expression and the formate overflow needed to create this trap, which the company believes provides a therapeutic selectivity window. One-carbon Therapeutics is targeting difficult-to-treat advanced refractory solid tumours. TH9619 is currently in the Phase 1/2 ODIN study. The company has stated that by identifying early signs of anti-tumour activity and guiding rational indication selection, it aims to build the foundation for a new generation of more precise and more tolerable cancer treatments. In May 2026, the company announced two significant developments: the appointment of Stefan Larsson and Raj Shah to its Board of Directors, and the acceptance of a trial-in-progress poster on the ODIN Phase 1/2 study of TH9619 for presentation at the 2026 ASCO Annual Meeting. These events reflect the company's progression as a clinical-stage biotechnology company advancing its lead asset through clinical development.

• Appointment of Stefan Larsson and Raj Shah to the Board of Directors.

• Announcement of trial-in-progress poster on ODIN Phase 1/2 study of TH9619 at the 2026 ASCO Annual Meeting.

Clinical-stage biotechnology company pioneering first-in-class anti-cancer therapies that exploit cancer's oncogene addiction and one-carbon metabolism dependency.

• TH9619

  First-in-class, potent, small-molecule dual inhibitor of MTHFD1/2 that selectively kills cancer through folate trapping. Currently in Phase 1/2 ODIN study for advanced refractory solid tumours.

1. 1Home - One-carbon Therapeuticsone-carbon.com
2. 2About us - One-carbon Therapeuticsone-carbon.com
3. 3One-carbon Therapeutics AB (Sweden) - Wikidatawikidata.org